Lanreotide subcutaneous injection – Cipla — Medica
Neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, thymus (carcinoid tumors), and pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptide-secreting tumors [VIPomas], insulinomas)
Initial criteria
- Medication is prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist
Approval duration
1 year